JP2015524474A - 治療レジメン - Google Patents

治療レジメン Download PDF

Info

Publication number
JP2015524474A
JP2015524474A JP2015526649A JP2015526649A JP2015524474A JP 2015524474 A JP2015524474 A JP 2015524474A JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015526649 A JP2015526649 A JP 2015526649A JP 2015524474 A JP2015524474 A JP 2015524474A
Authority
JP
Japan
Prior art keywords
composition
subject
agonist
disorder
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015526649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524474A5 (https=
Inventor
シチョン，ニコラス，ジー．
パイク，ロバート，イー．
コフマン，ジョン，エフ．
Original Assignee
エスワン バイオファーマ インコーポレイテッド
エスワン バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスワン バイオファーマ インコーポレイテッド, エスワン バイオファーマ インコーポレイテッド filed Critical エスワン バイオファーマ インコーポレイテッド
Publication of JP2015524474A publication Critical patent/JP2015524474A/ja
Publication of JP2015524474A5 publication Critical patent/JP2015524474A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015526649A 2012-08-06 2013-08-06 治療レジメン Ceased JP2015524474A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06
US61/679,999 2012-08-06
PCT/US2013/053843 WO2014025814A1 (en) 2012-08-06 2013-08-06 Treatment regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018103554A Division JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Publications (2)

Publication Number Publication Date
JP2015524474A true JP2015524474A (ja) 2015-08-24
JP2015524474A5 JP2015524474A5 (https=) 2016-10-20

Family

ID=50068530

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015526649A Ceased JP2015524474A (ja) 2012-08-06 2013-08-06 治療レジメン
JP2018103554A Pending JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018103554A Pending JP2018150357A (ja) 2012-08-06 2018-05-30 治療レジメン

Country Status (15)

Country Link
US (1) US9517254B2 (https=)
EP (1) EP2879680A4 (https=)
JP (2) JP2015524474A (https=)
KR (4) KR20230136142A (https=)
CN (2) CN104884060A (https=)
AU (2) AU2013299725A1 (https=)
BR (1) BR112015002687A2 (https=)
CA (1) CA2881388A1 (https=)
EA (1) EA201590349A1 (https=)
HK (2) HK1211239A1 (https=)
IL (1) IL237150B (https=)
MX (1) MX2015001695A (https=)
SG (3) SG10201709967YA (https=)
WO (1) WO2014025814A1 (https=)
ZA (1) ZA201501562B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36742A (es) * 2016-06-17 2016-12-30 S1 Biopharma Inc Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025042884A2 (en) * 2023-08-21 2025-02-27 Kuleon Llc Serotonin receptor modulators for the treatment of addictions and overdoses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322085A (ja) * 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
JP2005506370A (ja) * 2001-10-20 2005-03-03 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 性的障害の治療におけるフリバンセリンの使用
JP2007525442A (ja) * 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
JP2008150371A (ja) * 2006-12-15 2008-07-03 Pfizer Ltd 性機能障害を治療するための化合物
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
JP2012500801A (ja) * 2008-08-21 2012-01-12 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ Ｃｎｓ疾患の治療法
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
CN1946404A (zh) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
SG10201609297VA (en) * 2011-04-04 2016-12-29 S1 Biopharma Inc Treatment regimens

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322085A (ja) * 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
JP2005506370A (ja) * 2001-10-20 2005-03-03 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 性的障害の治療におけるフリバンセリンの使用
JP2007525442A (ja) * 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
JP2008150371A (ja) * 2006-12-15 2008-07-03 Pfizer Ltd 性機能障害を治療するための化合物
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
JP2012500801A (ja) * 2008-08-21 2012-01-12 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ Ｃｎｓ疾患の治療法
JP2012515720A (ja) * 2009-01-20 2012-07-12 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Drug points: Increased female sexual response after oxytocin", BMJ, vol. vol.309:929, JPN6018034843, 1994, ISSN: 0003873844 *
CESKA A SLOVENSKA PSYCHIATRIE, vol. 104(suppl.2), JPN6016003268, 2008, pages 1068 - 02, ISSN: 0003873841 *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 130, JPN6017019806, 1986, pages 265 - 272, ISSN: 0003873840 *
JOURNAL OF SEX & MARITAL THERAPY, vol. 26(3), JPN6016003272, 2000, pages 231 - 240, ISSN: 0003873842 *
PSYCHIATRY RESEARCH, vol. 160, JPN6017019803, 2008, pages 72 - 82, ISSN: 0003728937 *
SLEEP, vol. 23(5), JPN6016003265, 2000, pages 1 - 2, ISSN: 0003728932 *
UROLOGY, vol. 46(1), JPN6016003273, 1995, pages 117 - 120, ISSN: 0003873843 *

Also Published As

Publication number Publication date
KR20200128437A (ko) 2020-11-12
AU2018205121A1 (en) 2018-07-26
CN106924259A (zh) 2017-07-07
AU2013299725A1 (en) 2015-03-26
HK1211239A1 (en) 2016-05-20
SG10201908587PA (en) 2019-10-30
KR20230136142A (ko) 2023-09-26
CA2881388A1 (en) 2014-02-13
ZA201501562B (en) 2017-11-29
EP2879680A4 (en) 2016-06-01
US9517254B2 (en) 2016-12-13
KR20250041078A (ko) 2025-03-25
KR20150063039A (ko) 2015-06-08
IL237150B (en) 2018-07-31
US20150150946A1 (en) 2015-06-04
SG10201709967YA (en) 2018-01-30
WO2014025814A1 (en) 2014-02-13
MX2015001695A (es) 2015-09-28
IL237150A0 (en) 2015-04-30
HK1214505A1 (zh) 2016-07-29
BR112015002687A2 (pt) 2019-12-17
EP2879680A1 (en) 2015-06-10
CN104884060A (zh) 2015-09-02
SG11201500919PA (en) 2015-04-29
JP2018150357A (ja) 2018-09-27
EA201590349A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
JP2018150357A (ja) 治療レジメン
JP6563998B2 (ja) 治療計画
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
MX2008000248A (es) Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos.
WO2018075481A1 (en) Compounds, compositions and methods for treating or preventing depression and other diseases
CA2933921A1 (en) Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment
HK1240825A1 (en) Treatment regimens
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180530

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20180530

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20180612

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180806

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20180807

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180907

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20180911

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20181204

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20190312

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191203

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191217

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200714

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20200818

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200818

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20201222